LONDON – ProFibrix NV announced positive U.S. Phase II data for its Fibrocaps tissue sealant to add to positive results from the European Phase II published in November 2011, and is talking to investors at the J.P. Morgan Healthcare conference in San Francisco this week, looking to raise €20 million to €25 million (US$25.4 million to $31.8 million) for a pivotal Phase III trial.